Xponance, Inc. Madrigal Pharmaceuticals, Inc. Transaction History
Xponance, Inc.
- $9.68 Billion
- Q2 2024
A detailed history of Xponance, Inc. transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Xponance, Inc. holds 1,117 shares of MDGL stock, worth $242,389. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,117
Previous 893
25.08%
Holding current value
$242,389
Previous $238,000
31.09%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding MDGL
# of Institutions
297Shares Held
21.9MCall Options Held
757KPut Options Held
370K-
Janus Henderson Group PLC London, X02.49MShares$539 Million0.38% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.06MShares$446 Million7.86% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$428 Million7.35% of portfolio
-
Rtw Investments, LP New York, NY1.92MShares$416 Million8.96% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny1.85MShares$401 Million39.74% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $3.71B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...